{
    "name": "daxibotulinumtoxinA",
    "comment": "Rx",
    "other_names": [
        "Daxxify",
        "daxibotulinumtoxinA-lanm"
    ],
    "classes": [
        "Neuromuscular Blockers",
        "Botulinum Toxins"
    ],
    "source": "https://reference.medscape.com/drug/daxxify-daxibotulinumtoxinA-4000078",
    "pregnancy": {
        "common": [
            "No available data are available on use in pregnant female to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data ",
                "description": [
                    "IM administration during pregnancy resulted in adverse effects on fetal growth (decreased fetal body weight and skeletal ossification) at maternally toxic doses approximately equivalent to 40x the maximum recommended human dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence in human or animal milk, effects on the breastfed infant, or effects on milk production",
            "Consider developmental and health benefits of breastfeeding along with the motherâ€™s clinical need and any potential adverse effects on the breastfed infant or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Distant spread of toxin effect",
                    "description": [
                        "Effects may spread from injection area to produce symptoms consistent with botulinum toxin effects ",
                        "These symptoms have been reported hours to weeks after injection ",
                        "Swallowing and breathing difficulties can be life threatening and there have been reports of death ",
                        "Not approved for any condition other than glabellar lines "
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to any botulinum toxin preparation, daxibotulinumtoxinA or its excipients ",
                "Presence of infection at proposed injection sites "
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Not interchangeable with other botulinum toxin products ",
                "Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received botulinum toxin injections for unapproved uses",
                "Serious and/or immediate hypersensitivity reactions have been reported for botulinum toxin products; reactions include anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea; if such a reaction occurs, discontinue further injection, and immediately institute appropriate medical therapy",
                "Adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes have been reported for botulinum toxin products; use caution when administering to patients with pre-existing cardiovascular disease",
                "Monitor with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) for increased neuromuscular compromise following botulinum toxin treatment; patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from administration",
                "Use caution when administering to patients with surgical alterations to the facial anatomy, marked facial asymmetry, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, inflammation at injection site(s), pre-existing eyelid, or eyebrow ptosis, when excessive weakness or atrophy is present in the target muscles, or the inability to substantially lessen glabellar lines even by physically spreading them apart",
                "Reduced tear production, reduced blinking, and corneal disorders may occur with use of botulinum toxins, including daxibotulinumtoxinA; dry eye has been reported with the use of botulinum toxin products in the treatment of glabellar lines; if symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patient to an ophthalmologist"
            ],
            "specific": [
                {
                    "type": "Spread of Toxin Effect",
                    "description": [
                        "Postmarketing safety data from other approved botulinum toxins suggest that botulinum toxin effects may be observed beyond local injection site",
                        "Symptoms include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties",
                        "Risk of symptoms is greatest in children treated for spasticity, but symptoms can occur in adults treated for spasticity and other conditions, and particularly in those patients who have underlying conditions that would predispose them to these "
                    ]
                },
                {
                    "type": "Dysphagia and breathing difficulties",
                    "description": [
                        "Treatment may result in swallowing or breathing difficulties",
                        "These reactions can occur within hours to weeks after injection with botulinum toxin",
                        "Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications",
                        "May be a consequence of weakening of muscles in injection area that are involved in breathing or swallowing",
                        "Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin products",
                        "When distant effects occur, additional respiratory mechanisms may be involved",
                        "Patients with respiratory disorders who may have become dependent upon accessory muscles may experience critical loss of breathing capacity ",
                        "If problems with swallowing, speech or respiratory disorders develop, immediately seek medical attention"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "No formal drug interaction studies conducted ",
                        "Use with caution owing to potential risk with the following",
                        "Aminoglycosides or other agents interfering with neuromuscular transmission ",
                        "Anticholinergic drugs",
                        "Botulinum neurotoxin products",
                        "Muscle relaxants"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases effects of daxibotulinumtoxinA by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases effects of daxibotulinumtoxinA by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "5-6"
        },
        {
            "name": "Injection site reactions",
            "percent": "6"
        },
        {
            "name": "Injection site pain",
            "percent": "4"
        },
        {
            "name": "Injection site erythema",
            "percent": "3"
        },
        {
            "name": "Injection site edema",
            "percent": "3"
        },
        {
            "name": "Injection site bruising",
            "percent": "1"
        },
        {
            "name": "Eyelid ptosis",
            "percent": "1-2"
        },
        {
            "name": "Edema",
            "percent": "2"
        },
        {
            "name": "Erythema",
            "percent": "2"
        },
        {
            "name": "Facial paresis",
            "percent": "1"
        },
        {
            "name": "Injection site papule",
            "percent": "1"
        },
        {
            "name": "Injection site pruritus",
            "percent": "1"
        }
    ]
}